The first patient has been dosed in an open-label Phase 1/2 clinical trial of AMT-162, uniQure's one-time gene therapy for SOD1-ALS.| ALS News Today
Marisa Wexler is a senior science writer for ALS News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of amyotrophic lateral sclerosis topics.| ALS News Today